Clearside Biomedical submits Xipere NDA to FDA

Clearside Biomedical announced that it has submitted a new drug application, or NDA, for Xipere to the FDA for the treatment of macular edema associated with uveitis. The uveitis market is expected to grow by 2024 to nearly $550M in the United States and over $1B globally. Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss worldwide, affecting approximately 350,000 patients in the United States and more than 1M worldwide. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.
https://thefly.com/landingPageNews.php?id=2839535